Researchers in a new study sought to report 10-year outcomes of treating hepatocellular carcinomas (HCCs) by combination therapy of chemoembolization and radiofrequency (RF) ablation. Combination therapy was administered in 277 patients with 382 treatment-naïve HCCs. Therapeutic effects, safety, survival rate, and prognostic factors were evaluated. They found that tumor enhancement disappeared after 466 RF sessions in all tumors, resulting in a complete response rate of 100 percent based on modified Response Evaluation Criteria In Solid Tumors. Local tumor progression developed in 15 patients during the mean follow-up of 44.9 months. Overall and recurrence-free survival rates were 56.3 percent and 22.5 percent at five years, and 23.5 percent and 9.3 percent at 10 years. The Child-Pugh class was the only significant prognostic factor detected in both the univariate and the multivariate analyses. The five-year and 10-year overall survival rates were 66.4 percent and 30.6 percent in 210 Child-Pugh class A patients. In addition to the Child-Pugh class, the maximum tumor diameter and the tumor number were significant independent factors affecting recurrence-free survival. No death was related to the combination therapy. Researchers concluded that RF ablation combined with chemoembolization is a safe and useful therapeutic option for treating HCCs.
To access the study in PubMed, click here.